Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.76 |
| ▸ | METAP2 | P50579 | 5/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.43 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15199357 | 0.89 | ACLY (0.62) | ACLYMETAP2METAP1ABCC1ABCG2 | |
| SCHEMBL21999597 | 0.87 | ACLY (1.00) | ACLYABCC1ABCG2PRSS12 | |
| SCHEMBL12469951 | 0.82 | CNR2 (0.63) | ACLYALDH1A1LMNAGAACRHBP | |
| SCHEMBL1107209 | 0.79 | ACLY (0.56) | ACLYALDH1A1GAAG6PDKMT2A | |
| SCHEMBL1097840 | 0.79 | ACLY (0.50) | ACLYALDH1A1G6PDKMT2AIL1RN | |
| SCHEMBL1099843 | 0.79 | ACLY (0.54) | ACLYLMNAKMT2A | |
| SCHEMBL1098803 | 0.77 | ACLY (0.52) | ACLYALDH1A1KMT2A | |
| SCHEMBL1098725 | 0.76 | ACLY (0.51) | ACLYALDH1A1LMNAGAACRHBP | |
| SCHEMBL1100199 | 0.76 | ACLY (0.51) | ACLY | |
| SCHEMBL1099596 | 0.74 | ACLY (0.49) | ACLYALDH1A1LMNAGAACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221787-B2 | Sulphonamine compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-12-29 | — | — | US | claimed |
| US-20130217759-A1 | Sulphonamine Compounds and Methods of Making and Using Same | ZAFGEN INC. (US) | 2013-08-22 | — | — | US | claimed |
| EP-2627632-A1 | SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051318-A1 | SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-04-19 | — | — | WO | claimed |
| US-9221787-B2 | Sulphonamine compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221787-B2 | Sulphonamine compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221787-B2 | Sulphonamine compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130217759-A1 | Sulphonamine Compounds and Methods of Making and Using Same | ZAFGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217759-A1 | Sulphonamine Compounds and Methods of Making and Using Same | ZAFGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217759-A1 | Sulphonamine Compounds and Methods of Making and Using Same | ZAFGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2627632-A1 | SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051318-A1 | SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217759-A1 | Sulphonamine Compounds and Methods of Making and Using Same | DNPEP, METAP2, ANPEP | ACLY 1062/4885METAP2 2/4885METAP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.